Tolvaptan in ADPKD Patients With Very Low Kidney Function
Vicente E. Torres, Ron T. Gansevoort, Ronald D. Perrone, Arlene B. Chapman, John Ouyang, Jennifer Lee, Hina Japes, Ali Nourbakhsh, Tao Wang
Abstract
INTRODUCTION: , respectively. METHODS: who had received placebo in REPRISE and began tolvaptan in OLE. The second comprised subjects who had received tolvaptan in REPRISE and were matched to REPRISE placebo-treated subjects for REPRISE baseline characteristics. Annualized eGFR slopes in REPRISE versus OLE were compared within the REPRISE placebo (i.e., placebo vs. tolvaptan treatment) and tolvaptan (i.e., 2 periods of tolvaptan treatment) subsets. RESULTS: < 0.001). In REPRISE tolvaptan subjects who continued tolvaptan in OLE, treatment effect was maintained (no difference between mean annualized eGFR slopes). CONCLUSION: .